From the blog

Trimodality Therapy for Malignant Pleural Mesothelioma

Published: May 3, 2011

Primary Outcome Measures:

  • To determine the overall 5-year survival rate. [ Time Frame: 5-years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

  • Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Morbidity
  • Number of Participants with treatment related deaths as a Measure of Safety and Tolerability [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Mortality
  • Recurrence [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Occurence of tumor recurrence

Eligibility & Criteria

Study Population
Patients with malignant pleural mesothelioma prsentint at the Deparment of Thoracic Surgery, HSK Wiesbaden
Inclusion Criteria:
  • Histologically confirmed diagnosis of MPM (all subtypes)
  • Clinical T1-3, N0-2, M0 disease.
  • No prior treatment for MPM.
  • Adequate renal and liver function
  • Adequate cardio-pulmonary reserves
Exclusion Criteria:
  • Patients with unresectable disease
  • Patients with an active infection that require systemic treatments
  • Patients with a concurrent active malignancy.
  • Patients with serious medical illness.
Contact Us
CONTACT INFORMATION
DIAGNOSIS
Have you received a diagnosis? *
reCAPTCHA